Patient demographics and baseline clinical characteristics
| Characteristic . | N = 22 . |
|---|---|
| Median age (range), y | 64 (43-92) |
| Female gender, n (%) | 9 (41) |
| White race, n (%) | 19 (86) |
| ECOG performance status 0/1/2, % | 32/64/4 |
| Stage of disease (Ann Arbor), n (%) | |
| I/II | 3 (14) |
| III | 9 (41) |
| IV | 10 (45) |
| B-cell lymphoma histology, n (%) | |
| FL, grade 1/2 | 9 (40) |
| DLBCL | 5 (22) |
| MCL | 3 (13) |
| Transformed FL | 2 (9) |
| SLL | 2 (9) |
| Burkitt lymphoma | 1 (4) |
| Median number of prior regimens (range) | 4 (1-8) |
| Refractory to most recent therapy, n (%) | 6 (27) |
| Prior regimens, n (%) | |
| Anti-CD20 antibody | 22 (100) |
| CHOP/CVP | 20 (91) |
| Bendamustine | 9 (41) |
| Stem cell transplantation | 9 (41) |
| Characteristic . | N = 22 . |
|---|---|
| Median age (range), y | 64 (43-92) |
| Female gender, n (%) | 9 (41) |
| White race, n (%) | 19 (86) |
| ECOG performance status 0/1/2, % | 32/64/4 |
| Stage of disease (Ann Arbor), n (%) | |
| I/II | 3 (14) |
| III | 9 (41) |
| IV | 10 (45) |
| B-cell lymphoma histology, n (%) | |
| FL, grade 1/2 | 9 (40) |
| DLBCL | 5 (22) |
| MCL | 3 (13) |
| Transformed FL | 2 (9) |
| SLL | 2 (9) |
| Burkitt lymphoma | 1 (4) |
| Median number of prior regimens (range) | 4 (1-8) |
| Refractory to most recent therapy, n (%) | 6 (27) |
| Prior regimens, n (%) | |
| Anti-CD20 antibody | 22 (100) |
| CHOP/CVP | 20 (91) |
| Bendamustine | 9 (41) |
| Stem cell transplantation | 9 (41) |
CVP, cyclophosphamide, vincristine, prednisone; ECOG, Eastern Cooperative Oncology Group; MCL, mantle cell lymphoma; SLL, small lymphocytic lymphoma.